Welcome to our dedicated page for Evolent Health SEC filings (Ticker: EVH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Evolent Health filings document the regulatory disclosures of a healthcare services company focused on complex specialty care and value-based care infrastructure. Its 8-K reports cover operating and financial results, material agreements, capital-structure matters, completed subsidiary transactions, and compensation arrangements tied to executive appointments.
Proxy materials disclose annual meeting matters, board oversight, director elections, executive compensation, and governance practices. Other current reports record board and officer transitions, equity incentives, and corporate events affecting Evolent Health, Inc. and its wholly owned subsidiary structure.
Evolent reported weaker second-quarter results with revenue of $444,328 thousand, down from $647,145 thousand a year earlier, and a net loss attributable to common shareholders of $51,090 thousand, or $0.44 per share, for the three months ended June 30, 2025. Operating expenses slightly exceeded revenue, producing a small operating loss, while interest expense rose versus the prior year and a $52,544 thousand loss on option exercise impacted six-month results.
On the balance sheet, the company held $150,995 thousand of cash and cash equivalents (total cash and restricted cash $177,970 thousand) and states it believes it has sufficient liquidity for at least the next twelve months. Total assets declined to $2,461,532 thousand from $2,544,411 thousand, long-term debt increased to $648,455 thousand from $490,520 thousand, and shareholders' equity fell to $896,005 thousand from $1,001,259 thousand. Operating cash used $25,769 thousand for the six months ended June 30, 2025, while financing provided $98,927 thousand, including $221,000 thousand of long-term debt proceeds.
Schedule 13G filed for Evolent Health, Inc. (CUSIP 30050B101). The filing, dated for the event 06/30/2025 and signed 08/06/2025, reports beneficial ownership by Morgan Stanley entities.
- Morgan Stanley (parent) reports 8,210,410 shares beneficially owned, representing 7.0% of Class A common stock with 0 sole voting power, 8,202,877 shared voting power and 8,210,410 shared dispositive power.
- Morgan Stanley Capital Services LLC reports 6,776,898 shares ( 5.8% ) with 0 sole voting/dispositive power and 6,776,898 shared voting and dispositive power.
- Issuer principal executive offices listed at 1812 North Moore St, Suite 1705, Arlington, VA 22209.
The filing is made under Rule 13d-1(b)/(c)/(d) format as a Schedule 13G and includes exhibits (Joint Filing Agreement and Item 7 information).
Key takeaways from Evolent Health (EVH) Form 4
Chief Financial Officer John Paul Johnson was granted 25,461 Class A restricted stock units (RSUs) on 1 July 2025 under the company’s Amended and Restated 2015 Omnibus Incentive Compensation Plan. The award was made at no cost (Transaction Code “A”) and increases his directly held stake to 309,245 shares.
The RSUs vest on a back-loaded schedule: 34 % on 1 July 2026 and 33 % on each of 1 July 2027 and 1 July 2028. This tranche represents the second portion of the 2025 annual equity cycle; issuance was contingent on shareholder approval of additional plan shares received at the 5 June 2025 annual meeting.
No open-market purchases, derivative transactions or sales were disclosed, and no earnings or cash proceeds are involved. The filing is therefore routine incentive compensation that strengthens executive equity alignment but has minimal direct financial impact on near-term valuation.